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ABSTRACT
Hepatitis B virus (HBV) pregenomic RNA contains
a hairpin structure (e) located in the preCore region,
essential for viral replication. e stability is enhanced
by the presence of preCore variants and e is
recognized by the HBV polymerase (Pol). Mutations
in the retrotranscriptase domain (YMDD) of Pol are
associated with treatment resistance. The aim of this
study was to analyze the preCore region and YMDD
motif by ultra-deep pyrosequencing (UDPS). To
evaluate the UDPS error rate, an internal control
sequence was inserted in the amplicon. A newly de-
veloped technique enabled simultaneous analysis of
the preCore region and Pol in the same viral genome,
as well as the conserved sequence of the internal
control. Nucleotide errors in HindIII yielded a UDPS
error rate <0.05%. UDPS study confirmed the possi-
bility of simultaneous detection of preCore and
YMDD mutations, and demonstrated the complexity
of the HBV quasispecies and cooperation between
viruses. Thermodynamic stability of the e signal was
found to be the main constraint for selecting main
preCore mutations. Analysis of e-signal variability
suggested the essential nature of the e structural
motif and that certain nucleotides may be involved
in e signal functions.
INTRODUCTION
Hepatitis B virus (HBV) is a double-stranded DNA virus,
whose genome (3.2kb) contains four Open Reading
Frames (OPFs) encoding seven proteins: surface antigens
(preS1, preS2 and HBsAg), polymerase (Pol), core protein
(HBcAg), X protein (HBx) and the soluble ‘e’ antigen
(HBeAg). During the viral cycle, HBV-DNA conform-
ation shows different phases: relaxed-circular, partially
double-stranded DNA in circulating viruses and cova-
lently closed circular DNA (cccDNA) within the hepato-
cyte nucleus. cccDNA acts as a mini-chromosome within
hepatocytes and transcribes ﬁve messenger RNA: preS1,
preS2, X, preCore and pregenomic RNA (pgRNA).
pgRNA is a greater than full-length HBV genome
(3.5kb) that codes for the Pol and HBcAg proteins. Pol
has two catalytic activities, reverse transcriptase (RT) and
RNaseH, and contains a spacer sequence and a terminal
protein (1).
In both the 50- and 30-ends of pgRNA, there is a redun-
dant sequence of 60nt that adopts a stem loop structure
(Figure 1a and b) and acts as encapsidation signal (E). The
50 sequence is crucial for Pol protein recognition and
binding to the 50 E structure (2). Pol triggers pgRNA en-
capsidation by core proteins, and initiates reverse tran-
scription (3). Pol employs an N terminal tyrosine residue
of the terminal protein domain as a primer to generate the
ﬁrst 4nt (4nt primer) of the DNA negative strand. This
4nt primer is covalently attached to Pol and uses the bulge
of the E signal as template (Figure 1a) (4). The 4nt primer
and Pol protein complex switches from the 50-t o3 0-end of
pgRNA and anneals to a 4-nt acceptor site within the
30 copy of direct repeat region 1 (Figure 1b) (5).
pgRNA and preCore mRNA share the same preCore
region, but code for different antigens: HBcAg (starting at
Position 1901 of the HBV genome) and HBeAg (starting
at Position 1814), respectively. Several preCore region mu-
tations abolish HBeAg expression. The most common is G
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Figure 1. (a) Stem-loop structure of the 50 HBV pgRNA. Main structural motifs (loops and stems), main codons studied (1, 14, 15, 28 and 29 of
preCore and 1 of Core genes), and the location of 4-nt primer annealing in the 50 pgRNA are indicated in the ﬁgure. (b) Stem-loop structure of the
30 HBV pgRNA. The acceptor site (AS), direct repeat region 1 (DR1), and the preCore and Core start codons are indicated in the ﬁgure.
8458 Nucleic Acids Research, 2011,Vol.39, No. 19to A at Position 1896 (G1896A), which changes a trypto-
phan (W) in codon 28 (TG1896G) to an amber stop codon
(TA1896G): pcW28stop. This substitution is often
associated with the G1899A change in codon 29
(pcG29D) (6). Other minor mutations have been
observed in codon 2 (CAA to TAA, Q2stop) and in
codon 1 (7). The pcW28stop change is reported to be re-
sponsible for 95% of HBeAg-negative patients in our
area, mainly in association with viral genotype D (8,9).
The G1896A and G1899A mutations have been associated
with secondary E structure stability and therefore, with
viral replication (8,10–12).
The main mutations conferring resistance to nucleoside
analogues, such as lamivudine (LMV), are predominantly
detected in the RT catalytic motif, YM204DD, in which
methionine (M) is changed to valine (V) or isoleucine (I)
(rtM204V and rtM204I) (13,14). Prolonged LMV therapy
is associated with a high probability (>70% after 5 years)
of resistance to treatment (15). After the ﬁrst year of
therapy, anti-HBe-positive patients have a signiﬁcantly
greater response than HBeAg-positive cases; however,
long-term response rates are compromised by the re-
appearance of HBV DNA in serum (16). Several factors
can have an effect on the selection rates of LMV-resistant
mutants: ethnic background, viral load, HBV genotype,
core promoter variants and preCore variants (17).
Ultra-deep pyrosequencing (UDPS) by GS-FLX
platform (Roche) has been used to detect clinically
relevant minority drug-resistant variants in treatment-
naı¨ve and experienced HIV-1 (18,19) and HBV patients,
thereby conﬁrming its ability to identify individual,
well-known mutations present in the Pol and HBsAg
genes at frequencies of 0.1–1% of the HBV quasispecies
(20,21). UDPS by GS-FLX platform is currently the only
technology that allows simultaneous quantitative analysis
of thousands of clonally ampliﬁed sequences of 200–250nt
in length for standard GS-FLX (longer fragments since
last year).
The aim of the present study was to analyze by UDPS
the HBV preCore region (thermodynamic structural re-
striction and variability of essential structural motifs of
the E signal) and its association with the RT catalytic
YMDD motif variants, with analysis of both regions in
the same sequence. However, these two regions are
separated by a distance of 1kb in the HBV genome,
making it difﬁcult to simultaneously study both regions
by classic cloning methodology (22,23). Therefore, our
methodological hypothesis was based on executing a
PCR that would encompass the preCore and YMDD
regions, using primers that include the HindIII site on
their 50-ends. After induction of intramolecular ligation,
a circular molecule was produced, which included the
YMDD Pol motif and the preCore region ﬂanking a
HindIII sequence. The integrity of the restriction site
sequence was used as the internal control to verify the
ﬁdelity of UDPS analysis.
PATIENTS AND METHODS
Patients
Seven chronically infected HBV patients, all males and
with a mean age of 36 years (range 17–50), were
included in the study. Patients were selected because
they had complete clinical documentation and known
viral characteristics by conventional techniques. They
had been treated with LMV for a mean of 25 months
because of high HBV DNA levels and elevated hepatic
biochemical markers. Two patients were HBeAg-positive
at baseline and e antigen loss did not occur during anti-
viral treatment. Genotype changes were not observed
during the study period. Baseline biochemical and sero-
logical markers, and treatment characteristics are
described in Table 1. All patients tested negative for
HCV and HIV markers. HBV serology, HBV DNA and
LMV-resistant mutations were tested every 3–6 months.
The circular construct used to analyze the preCore and
YMDD was obtained from four baseline samples
(Patients 1–4) and from four samples corresponding to a
time of viral breakthrough with mutations in the YMDD
motif (Patients 4–7).
Serology and HBV DNA assays
Serological markers for HBV (HBsAg, HBeAg and
anti-HBe), HCV (anti-HCV), hepatitis delta (anti-HDV)
and HIV (anti-HIV) were tested by commercial enzyme
immunoassays. HBV-DNA was quantiﬁed using
real-time PCR with a detection limit of 20IU/ml
(COBAS TaqMan HBV V2.0, Roche Diagnostics
GmbH, Mannheim, Germany). Main preCore mutations
Table 1. Baseline biochemical and serological markers, and treatment characteristics of the seven patients included in the study
ID Baseline Lamivudine treatment
HBV DNA
(IU/ml)
HBeAg ALT
(IU/ml)
HBV
genotype
Type
response
Months HBV DNA
(IU/ml)
ALT
(IU/ml)
Type mutation Rescue treatment
1 >10
8 N 392 D VBK 48 3.6 10
5 31 M204V LAM+ADV
2 6.6 10
6 N 167 A2 SVR 24 <20 30 – –
3 1.2 10
6 N 54 A2 SVR 24 <20 33 – –
4 >10
8 P 52 D VBK 12 6.2 10
6 281 M204IV LAM+TDF
5 3.3 10
6 N 78 A2 VBK 34 8.3 10
4 401 M204MIV LAM+ETV
6 >10
8 P 214 A2 VBK 24 1.3 10
7 93 M204V LAM+TDF
72  10
6 N 117 D VBK 12 2.2 10
4 103 L180LM LAM+ADV
SVR, sustained virologic response.
Nucleic Acids Research, 2011,Vol.39, No. 19 8459were detected by Sanger sequencing, as previously
described (8). HBV genotype and mutations conferring
treatment resistance were detected with LiPA
(INNO-LiPA, Innogenetics, Ghent, Belgium) (sensitivity
1–5%) and direct sequencing (sensitivity 20%) (24).
Generation of a circular construct containing the YMDD
motif and preCore region
HBV DNA was extracted from 200ml of serum with the
QIAamp DNA MiniKit (QIAGEN, Hilden, Germany).
With the aim of analyzing greatly separated regions in
the same genome, a 2.7-kb HBV DNA fragment including
the YMDD Pol motif and preCore region was PCR
ampliﬁed (Figure 2a), using the forward primer F1
(Position 1703) and reverse primer R1 (Position 1018)
(Table 2). The PCR reaction mix included 200mMo f
dNTPs and 400nM of each primer, and the method was
performed as follows: 30 cycles at 94 C for 30s, 55 C for
30s and 72 C for 3min, followed by 10 cycles at 94 C for
30s, 58.6 C for 30s and 72 C for 3min and a ﬁnal hold
at 72 C for 7min. The amplicon obtained was ampliﬁed
by nested PCR with primers that included the HindIII
restriction site sequence (AAGCTT) at the 50-end
(forward HindPcPol-F2, Position 1792, and reverse
HindPcPol-R2, Position 764) (Table 2) under the same
conditions as the ﬁrst PCR run, yielding a 2194-kb
product in genotype A2 samples and a 2155-kb product
in genotype D samples. To minimize ampliﬁcation errors,
Pfu UltraII (Stratagene, Agilent Technologies, La Jolla,
USA) polymerase was used in both PCR runs. The
nested amplicon was puriﬁed through 0.9% agarose gel,
digested for 1h at 37 C with HindIII (NEB, Ipswich,
USA), and puriﬁed again through 0.9% agarose gel. The
next step involved ligation of both HindIII ends of the
same fragment (intramolecular ligation) so that the two
regions of interest would come close enough in the same
molecule to be analyzed by UDPS (Figure 2a). Optimal
results were obtained with 0.5ng/m1 of the HBV
DNA-PCR fragment, and 1U of T4 DNA ligase (Roche
Diagnostics GmbH). The ligation product was loaded
onto 0.9% agarose gel; the band pattern obtained is
shown in Figure 2b. The band corresponding to the
HindIII circular construct (apparent size  1700bp)
(band a in Figure 2b) was cut from the gel and puriﬁed.
The identity of the circular constructs was conﬁrmed by
sequencing two overlapping PCR amplicons that cover the
complete circular construct sequence: a 1.2-kb amplicon
obtained with primers A3 and B3 and sequenced with C3,
D3 and E3 and a 1.8-kb amplicon obtained with primers
A4 and B4 and sequenced with A4, C4, D4 and C3
(primers described in Table 2). The fragment obtained
from sequencing the 1.3-kb amplicon, which includes the
preCore region, the YMDD motif and the HindIII se-
quences with C3 is shown in Figure 2c.
Simultaneous UDPS analysis of the YMDD motif and
preCore region
A 207-bp nucleotide fragment was PCR ampliﬁed from
the DNA recovered from band a (Figure 2b). All
HBV-speciﬁc primers included 50 adaptors as binding
sites for the pyrosequencing reaction (left 50 GCCTCCC
TCGCGCCA, right 50 GCCTTGCCAGCCCGC; both
ending with the TCAG barcode). The complete sequence
of UDPS-Primer A as forward and UDPS-Primer B as
reverse is shown in Table 2. Brieﬂy, PCR was performed
using 1  Pfu UltraII polymerase buffer, 10mM of each
dNTP, 20pmol of forward and reverse primers and 2.5U
of Pfu UltraII DNA polymerase (Stratagene, Agilent
Technologies) in a ﬁnal volume of 100ml. After a single
denaturation step of 2min at 95 C, samples underwent 30
cycles for 30s at 95 C, 30s at 60 C and 2min at 72 C, and
a single ﬁnal 10-min step at 72 C. Before UDPS, the
quality and length of the HBV DNA amplicons was
veriﬁed with the Agilent 2100 bioanalyzer (Agilent Life
Science, Santa Clara, CA, USA). The 207-bp fragment,
which included 163bp of the HBV-DNA sequence, under-
went UDPS with the 454 Life Science platform (GS-FLX,
Roche Applied Science), according to the manufacturer’s
protocol. Base calls and quality scores were determined
using the GS-Amplicon Variant Analysis software
(included in the GS-FLX platform).
Algorithm for interpreting sequence data
Data accuracy was validated according to previously
reported procedures (18,25,26). Brieﬂy, reads with inser-
tion–deletions, reads in which the primer did not match
the reference primer by at least 75%, those that did not
reach a ﬁxed length and those containing ambiguous calls
were discarded. A complementary reverse sequence was
obtained from the reverse sequence. The program
selected nucleotide sequences that passed the ﬁlter, and
the sequences were translated to amino acids for the poly-
merase and preCore regions (both regions are in-frame in
the circular construct). Several ﬁles were obtained and a
matrix of the frequency of changes at each amino acid
position in comparison with the master from each
patient was used. As was mentioned above, the circular
construct used as the target for UDPS analysis was the
result of intramolecular ligation of the HindIII 50- and
30-ends. Therefore, the integrity of this 6-bp restriction
enzyme sequence (AGGCCT) was a requirement for
correct ligation, and any nucleotide substitution in this
sequence would be a UDPS error. For this reason,
instead of using a more complex Poisson ﬁlter
(19,25,26), which needs UDPS processing of additional
clonal sequences (external control), the changes detected
in this 6-bp sequence were used to establish the cut-off
ﬁdelity of the UDPS process (internal control).
Analysis of RNA folding stability in the HBV pgRNA
encapsidation signal
Computer models of RNA folding and structure represen-
tations were obtained from the RNA Structure Fold
program (version 5.3), developed by Dr David H.
Mathews (27,28). All calculations were performed at a
temperature of 37 C. In keeping with Dr Mathews’
kindly provided suggestion, a script adaptation of the
RNA Structure Fold program (by command line
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Figure 2. (a) Schematic representation of the intramolecular ligation technique to obtain the preCore and YMDD Pol motif close to each other.
(1) The circle in a continuous line represents the complete HBV genome (3200bp). The semicircles in discontinuous lines represent the ﬁrst (ﬁrst
PCR, 2700bp) and the nested (2194bp for genotype A2 sequences and 2155bp for genotype D sequences) PCR products. (2) The product obtained
after intramolecular ligation and primers used to sequence the circular molecule (Table 2) are indicated in the ﬁgure. (b) Agarose gel obtained after
intramolecular digestion. Two markers (M-I and M-II) were loaded in the gel; band lengths are shown at the left side of the image. Two samples (S1
and S2) were loaded and four bands were detected; band lengths are indicated at the right side of the image. A band with an apparent size of 1700bp
was the circular molecule, with the preCore and YMDD Pol motif close to each other. Band B was the nested PCR product without ligation, and
band D were dimers of nested PCR products without ligation. Band C corresponded to the ligated dimers. B, C and D bands were not used, because
the main interest was to analyze regions from the same genome. (c) Sequence of the circular construct including the preCore region, YMDD
polymerase motif (in box), and HindIII sequence. PreCore (1, 2, 14, 15, 28 and 29) and Core (1) codons analyzed in the text are also enclosed in
boxes.
Nucleic Acids Research, 2011,Vol.39, No. 19 8461interfaces) was used to calculate the lowest free energy of
the E structure. Brieﬂy, each nucleotide sequence was auto-
matically converted to a ‘seq’ ﬁle, with the input format
required for the program. A ‘bat’ ﬁle was created for each
‘seq’ ﬁle, enabling execution of the Fold module of the
program for each sequence and creating the output ‘ct’
ﬁles, which contained the free energy of the structure.
The circular construct analyzed included nucleotides
from Positions 1814 to 1912, corresponding to the main
sequence of the 50 E signal (8,11,12). The sequences
obtained were used to calculate the epsilon energy of the
RNA ensemble. Because the epsilon energy data are not
normally distributed, between-group comparisons were
done using a permutation test based on the standard
t score for two groups. The Monte Carlo approach to
compute P-values was carried out, with n=2000
permutated samples. P-values in these comparisons were
corrected for multiple testing problems following the false
discovery rate procedure. The standard RNA-Structure
Fold (5.3) program was used to predict the secondary
structures of the 50 (Figure 1a) and 30 (Figure 1b)
(Position 1730–1930) E signals. Both predicted structures
showed a pseudo-triloop at the edge of the apical stem, as
has been demonstrated by magnetic resonance (MR)
analysis (29).
Phenotyping, mutagenesis and cell culture
A more than full-length HBV (1.1 genome unit) (able to
produce functional replicative pgRNA) from a patient
chronically infected with HBV genotype A was cloned in
pTriEx-mod vector (kindly provided by Dr F. Zoulim), as
described by Durantel et al. (30). This construct was used
to simulate HBV variants by site-directed mutagenesis. In
the present study, a thymine to cytosine mutation at
Position 1855 (T1855C) was generated, using the
Multi-Site-Directed Mutagenesis Kit (Agilent
Technologies), following the manufacturer’s instructions.
This is a silent change that does not induce an amino acid
substitution (both code for a cysteine). The forward
primer was Fw-T1855C, and the reverse primer
Rv-T1855C (Table 2). Because of the 60-nt redundancy
in HBV pgRNA, Position 1855 is repeated at the 50- and
30-ends. Thus, the mutagenesis process yielded three dif-
ferent constructs that contained the T1855C change at the
50-end, the 30-end or simultaneously at both ends.
Generation of these mutations was conﬁrmed by direct
sequencing of the clones with primers annealing
pTriEx-mod-1.1 HBV just before the HBV ligation
(promoter-Fw for the 50-end, and C1D1-Rv for the
30-end, shown in Table 2).
The three pTriEx-mod-1.1 HBV constructs were trans-
fected in Huh7 human hepatoma cells cultured in
Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 10% calf serum. Plasmid transfections were
performed using Fugene-HD (Roche Diagnostics GmbH).
Cells were seeded in 12-well plates at a density of 10
6 cells/
ml and were transfected at 80–90% conﬂuence, following
the manufacturer’s instructions. The supernatant was used
to quantify production of HBsAg (Architecht, Abbot
Diagnostics, Sigo, Ireland), HBeAg (Vitros,
Ortho-Clinical Diagnostics, High Wycombe, UK) and
HBV DNA (COBAS TaqMan HBV V2.0, Roche
Diagnostics GmbH). HBV DNA was extracted from the
supernatant (QiagenAMP DNA Mini Kit, Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions and used to evaluate HBV DNA production.
The HBV viral particle origin of HBV-DNA detected in
culture supernatants was conﬁrmed by differential PCR.
Brieﬂy, consecutive dilutions (1/1, 1/10, 1/10
2, 1/10
3 and
1/10
4) of extracted DNA were performed, and speciﬁc
Table 2. Sequences of primers used in the study
Name Position of the primer
and direction in HBV
genome (bold characters)
Sequence (50–30)
F1 1703, Fw YATAAGAGGACTCTTGGACT
R1 1018, Rv GCAAANCCCAAAAGACCCA
HindPcPol-F2 1792, Fw TACAAGCTTATTGGTCTGCGCACCAGC
HindPcPol-R2 764, Rv TACAAGCTTCTTGGCCCCCAATACCAC
A3 2489, Rv CCCMGTAAARTTYCCCACCTTAT
B3 245, Fw GTCTAGACTCGTGGTGGACTTCTCTC
C3 550, Fw ATGTWTCCCTCWTGTTGCT
D3 1864, Fw TCAAGCCTCCAAGCTGTGCC
E3 2267, Fw GGAGTGTGGATTCGCACT
A4 2270, Fw GTGTGGATTCGCACTCCTCCAG
B4 1927, Rv AAATTCTTTATAAGGGTCAATGT
C4 2817, Fw TCACCATATTCTTGGGAACA
D4 57, Fw TGCTGGTGGCTCCAGTTC
UDPS-Primer A 703, Fw GCCTCCCTCGCGCCATCAGGTAGGGCTTTCCCCCACTG
UDPS-Primer B 1931, Rv GCCTTGCCAGCCCGCTCAGCTCCAAATTCTTTATAWGGGTCRA
Fw T1855C 1834, Fw CTAATCATCTCTTGTACATGcCCCRCTGTTCAAGCCTCCAAGCTG
Rv T1855C 1879, Rv CAGCTTGGAGGCTTGAACAGYGGGgCATGTACAAGAGATGATTAG
C3-Rv 569, Rv AGCAACAWGAGGGAWACAT
pTriEx-Fw – TCTGCGCTCTGCTGAAGCCAGTTA
pTriEx-Rv – ACGATCGGAGGACCGAAGGAGCT
The position and direction of the 50 primer in the HBV genome (bold characters in the sequence), and the mutagenized position (bold lower cases)
are indicated
8462 Nucleic Acids Research, 2011,Vol.39, No. 19regions of HBV and pTriEx-mod were ampliﬁed, using the
paired primers C4 and C3-Rv for HBV, and pTriEx-Fw
and pTriEx-Rv for a 592-bp region of the plasmid (Table
2). Two negative controls were performed in the study,
one that contained only Fugene, which enabled evaluation
of Huh7 replication in the presence of the transfection
reagent, and another that contained only HBV DNA
without reagent. HBsAg and HBeAg tested negative, but
quantiﬁcation of HBV DNA was positive (2.15 10
2 UI/
ml). Differential PCR analysis, using primers for both
HBV and pTriEx ampliﬁcation, were positive only at a
dilution of 1/10. HBV PCR of wild-type and mutant
clones remained positive up to 1/10
3 to 1/10
4 dilutions,
indicating production of HBV DNA resulting from
HBV transfection of Huh7 cells. Ampliﬁcation of the
pTriEx region in HBV transfection reactions was only de-
tectable at a dilution up to 1/10; in further dilutions, PCR
was negative.
RESULTS
HindIII restriction sequence as internal control of UDPS
In the 200817 (Table 3) sequences analyzed, only 189nt
changes were observed at the HindIII restriction enzyme
site. Sixteen HindIII mutated sequences were found at a
frequency ranging from 1 to 24 (average, 22) and all
carried only one amino acid change. The single nucleotide
error rate was 1.6 10
 4 and the codon error rate was
4.7 10
 4. These values were considered the UDPS
error rates, and the cut-off for the sequence analysis was
set at 0.03% (twice the nucleotide error rate).
Analysis of the main preCore codons
PreCore codons 1, 2 and 28 were analyzed; changes in
these codons are the main cause of HBeAg
non-expression. The percentage of changes in each
sample processed is shown in Table 3. In four of the ﬁve
HBeAg-negative patients (Patients 1, 3, 5 and 7),
HBeAg-negative biochemical status was due to a stop
mutation in codon 28 (W28stop, main preCore
mutation). In Patient 2, HBeAg-negative status was due
to mutations in codon 1 of the preCore region (99.87%).
This mutation was also detected at a lower frequency in
Patient 6 (9.81%). Patients 2 and 6 were both infected with
genotype A2.
The circular construct included the E structure sequence
of the 50 pgRNA end. The base pairing rate between
Position 1896 in codon 15 and Position 1858 in codon
28 was analyzed. Among a total of 90386 sequences
with TA1896G in codon 28, 89837 (99.39%) showed
CCT1858 in codon 15 and among all sequences with
CCT1858 in codon 15, 99.76% showed TA1896G. These
results indicate that correct base pairing between
Positions 1896 and 1858 is an extremely important con-
straint in the G1896A mutation. The second most
frequent nucleotide substitution, G1899A (28.35%), was
paired with T1855 in 99.3% of cases, and was observed in
the presence of G1896A in 99.6% of cases.
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Nucleic Acids Research, 2011,Vol.39, No. 19 8463Conserved positions in the preCore region and
maintenance of base pairing in the basal and apical stems
A schematic representation of base-pairing between the
preCore positions analyzed, corresponding to E,i s
shown in Figure 3, which includes the percentage of nu-
cleotide and amino acid changes for all sequences.
Although a high level of conservation was observed,
there was a low percentage of variability ( 0.05%, close
to the UDPS error rate). Interestingly, the base-paired
positions in the basal (1851–1859 and 1895–1903) and
apical (1866–1877 and 1881–1894) stems showed similar
percentages of changes to maintain base-pairing.
Attending to the upper stem positions, a T to C change
in 1884, 1885 and 1893 was observed in >0.1% of se-
quences (0.15, 0.14 and 0.13%, respectively), with a com-
plementary change of A to G in their base-paired
Positions (1875, 1874 and 1867) in very similar percent-
ages (0.13, 0.1 and 0.13%, respectively). Additionally, the
low percentage (0.1%) of G to A changes in Position 1891,
which represent a new stop codon in the preCore sequence
(W26stop), were also compensated by a complementary C
to T change in a similar percentage (0.09%) in the
base-paired C1869T position. In all the apical stem pos-
itions, base-pairing of the structure was maintained.
The hexanucleotide edge of the upper stem (Positions
1877–1882) was also analyzed, with emphasis on the TGT
nucleotides (1878–1880), which form a pseudo-triloop
structure essential for pgRNA packaging (31). The
pseudo-triloop was found to be highly (but not complete-
ly) conserved (99.5% of cases). Four variants were
detected at a frequency of >50 relative to the master:
403 CGT, 330 TGC, 118 TAT and 66 AGT. Among the
three nucleotides, the most highly conserved was G1879
(0.06% variability), and this was one of the most highly
conserved nucleotides in the complete E signal. Outside the
pseudo-triloop, C1882 showed 0.15% variability, and the
single nucleotide bulge T1889, located in the middle part of
the apical stem, had 0.2% variability (Figure 3).
Interestingly, the most frequent changes in the E struc-
ture were located in the basal stem (G1896A and
G1899A), where the rule of base-pairing maintenance
was also observed (see ‘Analysis of main preCore
codons’). The low percentage of T to C changes (0.3%)
in Position 1855 was surprising considering that this
change did not induce an amino acid substitution. Its com-
plementary base, Position 1899, showed a higher rate of
G to A mutations (28.3%), despite that fact that a signiﬁ-
cant amino acid change (G29D) was produced. Study of
Position T1855 to C by mutagenesis is described in the
next section.
Stability of the pgRNA 50 e signal: free energy of the
stem loop structure
The free energy of the thermodynamic ensemble of the
stem loop structure of the pgRNA 50 E signal was
calculated for all sequences obtained by UDPS analysis
(energy values for master sequences shown in Table 3).
The distribution obtained, attending to HBV genotype
and the presence (mutated) or absence (wild-type) of mu-
tations in preCore codons 1 (pc1) and 28 (pc28) is shown
in Table 4. An analysis was performed between values
from the same genotype group; however, comparisons
including pcC1 were not taken into account because the
ﬁrst preCore codon (pc1) is not present in the pgRNA
50-end (it starts at Position 1818). The presence of a
mutation in pc28 destabilized the E structure in genotype
A2 sequences (higher energy in codon 28 mutations),
whereas in genotype D, the opposite was observed,
indicating that in this case, pc28 mutations stabilize the
E structure (lower energy in pc28 mutations).
The low percentage of T to C changes in Position 1855
mentioned above was even more surprising when stabil-
ization energy was calculated. The rare T1855C (0.30%)
variant showed the lowest energy value ( 30.1kcal/mol in
genotype A2) and therefore, the highest theoretical
thermodynamic stability. This observation, in addition
to the ﬁnding that T1855C did not induce an amino acid
change, prompted us to mimic the T1855C mutation by
site-directed mutagenesis. Two clones that are found in
natural HBV replication were used to transfect Huh7
cells: the WT clone and another with the 1855C
mutation in both the 30- and 50-ends. Two more clones
with the mutation in only one of the two pgRNA ends
were selected to analyze possible differences in the nucleo-
tide depending on its location in pgRNA. Each transfec-
tion was performed at least six times and detailed results
of the average expression of HBsAg, HBeAg and HBV
DNA are shown in Table 5. In the presence of the
double 50 plus 30 mutation, HBsAg, HBeAg and
HBV-DNA had systematically lower values than T1855
WT, indicating a possible essential nature of the nucleo-
tide. Surprisingly, quantiﬁcation of HBsAg, HBeAg and
HBV DNA yielded higher levels in clones carrying only
one mutation in either the 50-o r3 0-end.
The 4-nt bulge and the acceptor site
The E structure bulge contains 4nt (TTCA) that act as the
template for synthesizing the 4nt primer to start minus
DNA strand synthesis. This small sequence shifts from
the 50 bulge to an acceptor site (AS) located in the 30
direct repeat region 1 (DR1) (Figure 1b). Conservation
of the 4-nt bulge and AS in DR1 seemed to be essential
for HBV replication; hence, both regions were analyzed.
Variants occurring at a frequency of >50 (2-fold the most
prevalent variants in the HindIII control sequence:
>0.03%) were considered signiﬁcant. A total of 189737
sequences were included, and the vast majority (98.53%)
showed the same sequence in the bulge and DR1 regions.
The remaining sequences (N=2783, 1.47%) contained
changes that prevented complete annealing of 4nt
primer in the AS DR1 site, due to a single nucleotide
substitution. Less than a third of mutated sequences
(N=920, 0.48%) contained the change only in the
bulge sequence, while in the other cases (N=1863,
0.98%), the change was only present in the AS of DR1.
The 2783 sequences without correct homology between
the 4nt primer (TTCA) and the AS DR1 site were classi-
ﬁed into nine different variants by homology of the
bulge sequence (Figure 4): variants 1–4 were deﬁned by
mutations within the bulge (Positions 1863–1866) and
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0 0,17 00 0,18 1880 T
0,06 00 0 0,06 1879 G
0,21% P L 22 0,03 0,21 0 0,01 0,26 1878 T
0,02 0 0,06 0 0,08 1877 CG 1881 0,05 0,05 000
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0,01 0 0,06 0 0,08 1873 CG 1886 0,15 0,09 0 0,05 0
0,21% P 00 0,06 0 0,07 1872 CG 1887 0,12 0,08 00 , 0 4 0 25 G
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68,6% S T 13 00 0,10 0 0,11 1851 CG 1903 0,13 0,13 000 0,13% I
0 0,07 68,62 0,04 68,73 1850 A
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0,01 0,19 00 0,21 1832 T
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Q2 00 0,02 0,10 0,13 1818 A
00 0,06 0 0,07 1817 C
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Figure 3. Schematic representation of base pairing between the preCore positions analyzed, which correspond to the stem–loop structure.
The columns in the center indicate the consensus sequence obtained from the laboratory’s entire collection of genotypes A sequences (bold char-
acters). The ‘Nucleotide changes’ column indicates the percentage of each nucleotide change (%A, %C, %T and %C) and the total changes (%Tot)
for all positions, attending to the master sequence. The ‘Amino acid (AA) changes’ column indicates the codon representing the position (N), the
amino acid coded from the master sequence (WT), and the percentage of sequences that code for a different amino acid (%MT).
Nucleic Acids Research, 2011,Vol.39, No. 19 8465variants 5–9 by mutations within the DR1 AS (Positions
1824–1827). Sequences from variants 5–9, which repre-
sented 1232 cases (44 0.65% of total sequences), showed
complete 4-nt homology with a sequence located in
Positions 1849–1852 (TTCA corresponding to HBV
genotype D), which was considered a putative acceptor
site (AS3). Variant 3, with 119 sequences (4, 0.06% of
the total) showed 3-nt homology with an upstream AS3
sequence. The sequence groups of variants 2, 4, 8 and 9
(N=864 cases; 31, 0.46% of the total) showed 3-nt
homology with alternatives to the AS sequences located
at Positions 1818–1823 [‘o’ or AS2 in Positions 1835–1846
(27)]. Lastly, 568 sequences (20.5, 0.28% of the total) had
an AS canonical region. In summary, when sequences of
the 4nt bulge primer and its AS DR1 canonical site were
not completely complementary, 44% of cases showed 4-nt
homology with the putative AS3 acceptor site (HBV
genotype A2 characteristic sequence) while the remaining
56% showed only 3-nt homology, mainly located in pre-
viously described alternative acceptor sites (32).
YMDD analysis
The YMDD motif was analyzed in four baseline samples
and in four samples containing LMV-resistant mutations,
detected by InnoLipa. Percentages of the sequences
obtained with different nucleotides are shown in
Table 3; the columns indicate the amino acid detected.
The wild-type form was represented as methionine (M),
and mutants conferring resistance were valine (V) and iso-
leucine (I). Amino acids other than M, V or I, detected in
a lower percentage, were grouped as ‘Others’. As was seen
in the baseline samples, the wild-type form of Position 204
was highly predominant (>99%), but in the four samples,
a low percentage of the main rtM204V/I mutant forms
(0.07–0.2%) and a signiﬁcant percentage of other
variants (0.09–0.12%) were detected. In the four samples
corresponding to a time of viral breakthrough (VBK)
analyzed, the LMV-resistant variants rtM204V/I were
the main populations (98.7–99.7%). However, low
1814   1820       1830        1840       1850       1860       1870        1880       1890       1900
*.....*.........*.........*.........*.........*.........*.........*.........*.........*....
- - - e g l u B - - - - - - - - 1 R D
AS1---AS-- AS2--------- AS3------ 4NT-
Master 5’-ATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’
-------------------------------------------------------------------------- ----------------------------------------
1 5’-ATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATGTCCtACTGTTCGAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 275 (0.15%)
----------------------------------------------------------------------------------------------------------------- ------------
2 5’-ATGCAACTTTTTCACCTCTGCCTAATCATCTCaTGTTCATGTCCtACTGTTTAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 67 (0.04%)
----------------------------------------------------------------------------------------------------------------- ------------
3 5’-cTGCAACTTTTTCACCTCTGCCTAATCATCTCaTGTTCATGTCCtACTGTCCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 119 (0.06%)
---------------------------------------------------------------------------------------------------------------- -------------
4 5’-cTGCAACTTTTTCACCTCTGCCTAATCAcCTCTTGTtCATGTCCtACTGCTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTaGGaCATGG-3’ 459 (0.24%)
------------------------------------------------------------------------------------------------------------------ -----------
5 5’-ATGCAACTTTTTCCCCTCTGCCTAATCATCTCATGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTaGGaCATGG-3’ 234 (0.24%)
5’-cTGCAACTTTTTCCCCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 228 
------------------------------------------------------------------------- ----------------------------------------------------
6 5’-ATGCAACTTTTTCGCCTCTGCCTAATCAcCTCaTGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTaGGaCATGG-3’ 212 (0.15%)
5’-ATGCAACTTTTTCGCCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 65 
------------------------------------------------------------------------------------------------------------------ -----------
7 5’-cTGCAACTTTTTTACCTCTGCCTAATCAcCTCaTGTTCATGTCCtACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTaGGaCATGG-3’ 291 (0,15%)
------------------------------------------------------------------------------------------------------------------ -----------
8 5’-ATGCAACTTTTCCACCTCTGCCTAATCAcCTCaTGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 260 (0.22%)
5’-CTGCAACTTTTCCACCTCTGCCTAATCAcCTCTTGTACATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 159 
------------------------------------------------------------------------------------------------------------------ -----------
9 5’-ATGCAACTTTCTCACCTCTGCCTAATCATCTCATGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 235 (0.22%)
5’-CTGCAACTTTCTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGG-3’ 179
---------------------------------------------------------------------------- -------------------------------------------------
Figure 4. Sequences without correct homology between the 4nt primer in the bulge (1863–1866) and acceptor site (AS) in direct repeat region 1
(DR1) (1824–1827). The genotype A2 consensus sequence from our laboratory collection used as the pattern is presented in the ﬁrst line, and variants
are added below. The number of sequences of each variant and the percentage of the total represented is indicated at the end of each line. Bold
characters indicate mutations from the master, and lower cases indicate a mixture with the nucletotide of the consensus sequence. Boxes indicate
homologous sequences and suggest alternative ASs.
Table 4. Epsilon energy distribution attending to HBV genotype and
the presence or absence of mutations in the preCore (codons 1 and
28)
Genotype 28 1
WT MT
A2 WT  25.44a  25.98c
MT  24.30b  23.79d
DW T  23.76e  24.81g
MT  24.39f  25.48h
a versus b: P=0.001; a versus c: P=0.006; a versus d: P=0.018;
b versus c: P=0.001; b versus d: P=NS; c versus d: P=0.001;
e versus f: P=0.0015; e versus g: P=0.0210; e versus h: P=0.0015;
f versus g: P=NS; f versus h: P=0.0210; g versus h: P=NS
a versus e: P=0.002; b versus f: P=NS; c versus g: P=0.007;
d versus h: P=0.013.
Table 5. Average expression of HBsAg, HBeAg, and HBV DNA in
the different transfection experiments
Experiment HBsAg
(IU/ml)
HBeAg
(arbitrary units)
HBV DNA
(log IU/ml)
Wild-type (T1855) 65.89 5.52 6.5
1855C mutation in 50 and 30 55.47 3.58 6.1
1855C mutation in 50 115.90 6.96 6.3
1855C mutation in 30 175.37 11.70 6.8
8466 Nucleic Acids Research, 2011,Vol.39, No. 19percentages of wild-type sequences were also detected
(0.07–1.06%). In three patients with VBK (cases 4, 6
and 7) the rtM204V mutation was predominant, but
Patient 4 had the predominant mutation in combination
with a considerable percentage of rtM204I (5.6%). The
rtM204I mutation alone predominated in Patient 5, but
a small percentage (0.2%) of rtM204V was also detected.
These results agree with those obtained by Lipa (Table 1).
Interestingly, the percentage of ‘Other’ variants in
Position 204 (0.23–0.27%) was higher in VBK samples
than in baseline samples, suggesting that these variants
might also be involved in LMV resistance.
Simultaneous detection of preCore and polymerase gene
mutations in the same HBV genome
The possibility of simultaneous mutations in the
YM204DD Pol motif (Position 204) and preCore (codon
1, 2 and 28) genes was analyzed in the eight circular con-
structs processed. Sequences were grouped according to
the presence or absence of mutations in the four regions
(preCore codons 1 and 2 were analyzed together), and the
percentages found are shown in Table 6. In Patients 5 and
7, who were both HBeAg-negative and had mutations
against LMV, the sequences showing simultaneous muta-
tions in the preCore and Pol genes comprised the major
populations. Interestingly, sequences carrying mutations
in the preCore and Pol genes were detected in signiﬁcant
percentages in all cases, particularly Patient 6, in whom
9.9% of sequences showed simultaneously occurring LMV
mutations and preCore codon 1 mutations.
Sequential study of the preCore region and YMDD motif
In Patient 4, the circular construct was obtained from
samples taken at baseline and at VBK. Mutations
conferring LMV resistance were detected in the baseline
sample (0.55%), and were much more prevalent at VBK
(99.54%) (Table 3). Although the rt204I mutation was
detected in a higher percentage than rt204V at baseline
(0.47% versus 0.08%), rt204V was more frequent
(93.9%) than rt204I (5.63%) at VBK. As to preCore
mutations, the percentage of stop codon 28 signiﬁcantly
decreased at VBK (0.12%) relative to the baseline sample
(8.31%) (Table 3).
Start codon of the core gene
The circular construct included the start codon of the Core
gene, and signiﬁcant percentages (0.11–0.91%) of muta-
tions in this codon were detected in all samples processed
(Table 3). It must be kept in mind that these mutations
abolished Core protein production; hence HBV genomes
carrying these changes would be defective for viral capsid
production.
preCore fragment overlapping the HBx gene
The HBx gene spans Position 1374–1838 of the HBV
genome, overlapping the preCore gene in the last eight
codons (Positions 1814–1838). For this reason, mutations
in the HBx stop codon (Positions 1836–1838) and its im-
plications on the preCore ORF were analyzed. Although
most sequences (194423; 96.82%) had the expected TAA
stop codon, 5837 sequences (2.9%) carried the TAG
amber stop codon, which represents an isoleucine to
valine amino acid substitution in the overlapping
preCore region (ATC to GTC). Of note, a signiﬁcant per-
centage of sequences (324, 0.16%) showed a T1836C sub-
stitution, which changes the ochre stop codon TAA to
CAA (Gln). After this substitution, the HBx protein
would be translated to the next in-frame stop codon
TAG at Position 1992, inducing expression of 51 addition-
al amino acids at the COOH-terminal region. In the
preCore ORF, the T1836C mutation also induces a
change of leucine to proline. The remaining 233 sequences
showed other amino acid substitutions, which were not
analyzed because they occurred at a frequency below
our established cut-off.
DISCUSSION
The circular construct developed in the present study
provided information about the HBV RT YMDD Pol
and preCore regions, thus enabling analysis of simultan-
eous mutations in both regions of the same genome. The
obligate presence of the 6-bp HindIII sequence, which
Table 6. Percentage of sequences, depending on the presence or absence of mutations in YMDD and preCore positions
YMDD preCore Baseline Samples VBK samples
Pt 1 Pt 2 Pt 3 Pt 4 Pt 4 Pt 5 Pt 6 Pt 7
HBe N HBe N HBe N HBe P HBe P HBe N HBe P HBe N
204 Codon 1-2
a Codon 28 Gen D Gen A2 Gen A2 Gen D Gen D Gen A2 Gen A2 Gen D
Wt Wt Wt 0.20 0.05 0.04 90.93 0.25 0.00 0.05 0.00
Wt Mt Wt 0.00 99.41 0.00 0.55 0.00 0.03 0.00 0.00
Wt Wt Mt 99.21 0.01 99.71 7.82 0.00 0.04 1.01 0.07
Wt Mt Mt 0.30 0.16 0.14 0.03 0.00 0.01 0.00 0.00
Mt Wt Wt 0.01 0.00 0.00 0.21 97.94 0.13 88.78 0.29
Mt Mt Wt 0.00 0.29 0.00 0.00 0.59 0.00 9.86 0.01
Mt Wt Mt 0.29 0.08 0.11 0.46 1.20 99.24 0.28 99.03
Mt Mt Mt 0.00 0.00 0.00 0.00 0.02 0.56 0.02 0.60
The negative (N) or positive (P) status of HBe antigen expression and HBV genotype (Gen A2 or D) are indicated in each patient column.
Bold values indicate percentages higher than 1%.
aWT codon 1 and 2 are not mutated. MT codon 1 and/or codon 2 are mutated. However, mutations are mainly found in codon 1.
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ﬁdelity of the UDPS process. The calculated nucleotide
error rate (1.6 10
 4), with more transitions than
transversions (60% versus 40%), was similar to reported
error rate values obtained with clonal DNA as the external
control (18–20,26,25), thus validating the use of HindIII
as the exclusive error rate control. Nonetheless, to be more
precise and concise, only variants in a percentage higher
than twice this error rate (>0.03%) were taken into
consideration.
Analysis of the YMDD motif of the Pol gene conﬁrmed
the presence of low but signiﬁcant percentages
(0.07–0.55%) of LMV resistance mutations in baseline
samples from all patients studied, thus illustrating the
complexity of the HBV quasispecies. Interestingly, signiﬁ-
cant populations of other YMDD variants (0.09–0.12%)
were also detected at baseline. At VBK, the rtM204V/I
variants were the main populations detected
(99.7–93.9%), but wild-type sequences were also found
in small percentages (0.07–1.06%). Once again, the
presence of YMDD variants was associated with LMV
resistance (14). Variant rtM204V was predominant in
three of four cases of VBK, whereas rtM204I was predom-
inant in only one. In the sequentially studied case, rt204I
was detected in a higher percentage than rt204V at
baseline (0.47% versus 0.08%), but after VBK, rt204V
was more prevalent (93.9%) than rt204I (5.63%). This
suggests that the type and relative frequency of mutations
at baseline does not predict the mutations selected during
treatment (33).
The high percentages of viral populations with preCore
and LMV-resistant mutations observed in LMV-resistant
anti-HBe cases seem to indicate that mutations in these
regions simultaneously occur in the same genome. In the
limited available studies directly investigating this simul-
taneous presence (22,23), there were no correlations of
LMV-resistant mutations with HBV genotype or the
presence (or not) of the preCore stop codon.
Furthermore, in vitro study has shown that progeny
DNA levels were restored in constructs with preCore
and LMV mutations (34,35). Only a small number of
clones were analyzed in the previous studies (22,23)
because the preCore and YMDD regions are more than
1kb apart, a fact that makes their study difﬁcult. When
the present research was performed, clonal analysis by
UDPS was limited to a 250-bp sequence length ( 400bp
in its current version). Nonetheless, the methodology
reported here enabled ultra-deep clonal study of both
types of variants in the same genome. The results
obtained with this novel PCR-based technique support
the idea that simultaneous mutations in the preCore
region and YMDD Pol motif are common in the HBV
quasispecies in CHB patients, regardless of the viral
genotype (A2 or D) or HBeAg status.
The presence of genomes without the Core antigen start
codon suggests the existence of minor viral populations
that are defective for viral capsid production, another in-
dication of the complexity of HBV viral quasispecies. The
presence of these genomes in HBV infection can be
explained by possible collaboration between viruses
from the same infection by a trans-complementation
mechanism: if wild-type and Core-defective genomes
coinfect the same liver cells, Core proteins produced in
excess by the wild-type viral genome might be used to
encapsidate Core-defective HBV genomes. Possible reduc-
tion of HBV core proteins in the cytoplasm pool due to
the presence of Core-defective genomes could decrease
their expression in the cell membrane, thus modulating
host immune pressure and maintaining the infection.
Therefore, the presence of defective genomes might estab-
lish cooperation with wild-type viruses, thus favoring viral
ﬁtness. This mechanism of trans-complementation has
been described in in vitro studies analyzing defective
HBV Core clones (36). Further mutagenic studies are
needed to evaluate the possible decrease in host immune
response in this situation. Research evaluating possible
roles of the minor (0.16%) mutated sequences detected
(additional amino acid in the HBx COOH-terminal
peptide due to a mutation in the HBx stop codon)
would also help to clarify the role of the HBx gene in
HCC pathogenesis.
In agreement with previous studies (37), the two
HBeAg-positive cases had signiﬁcantly higher percentages
of preCore stop mutations in codon 28 (8.31 and 1.31%),
suggesting easy selection of preCore mutations when the
host immune response increases during viral infection.
Likewise, in HBeAg-negative patients, wild-type codon
28 preCore genomes were detected in lower percentages
(0.02–0.14%), explaining cases of natural or LMV-related
seroreversion (38,39). An interesting observation in the
longitudinally studied patient was the signiﬁcant
decrease in the main preCore mutation at VBK, which
coincides with reports suggesting that HBV strains
carrying preCore stop codon 28 and no Pol resistant
variants are more sensitive to LMV treatment than
preCore wild-type sequences (35,38,39). However, add-
itional longitudinal UDPS analyses, as reported in the
present study, must be performed to further substantiate
this possibility.
Epsilon elements are present twice on pgRNA, one
located near the 50 terminus and the other at the 30
terminus. Correct base-pairing between Position 1896
(codon 28) and 1858 (codon 15) from the lower stem of
the encapsidation signal is one of the main constraints for
preCore variability and E thermodynamic stability, as has
been reported previously (8) and was highly reinforced by
our results. Regarding HBV genotypes, the main preCore
mutation (A1896G variant) was clearly predominant in
genotype D, while in genotype A2, signiﬁcant percentages
of preCore mutation were located at codon 1. This
thermodynamic restriction between HBV genotypes cor-
roborates results from previous studies using clonal or
direct sequencing techniques (8,11).
After initial E-Pol binding, the HBV apical stem loop of
E has to open up to form a primer synthesis-competent
complex, but the highly stable HBV upper stem is a
barrier. The free energy to overcome this barrier may
come from interaction with RT and by capping the TGT
pseudo-triloop with capsid proteins (31). Highly
conserved positions and maintenance of correct base
pairing in the upper stem were observed in our results.
A change of T to C in Positions 1884, 1885 and 1893
8468 Nucleic Acids Research, 2011,Vol.39, No. 19was found in 0.15, 0.14 and 0.13%, respectively, but inter-
estingly, the complementary change of A to G in their
base-paired Positions (1875, 1874 and 1867) showed very
similar percentages (0.13, 0.1 and 0.14%, respectively).
Additionally, the low percentage (0.1%) of G to A
changes detected in Position 1891, which in fact represent
a new stop codon in the preCore sequence, was also
compensated with complementary C to T changes in a
similar percentage (0.09%) in the 1869 base-paired
position. Observation of correct base pairing of the
apical and upper stem of E might reinforce the idea that
structural rather than sequence restrictions are involved in
conservation of the E encapsidation signal.
The hexanucleotide sequence located at the top of the
apical stem (from 1877 to 1882) was found to be highly
conserved among 1200 HBV strains (40). MR analysis (41)
has shown that the 1878TGT1880 sequence folds in a
pseudo-triloop (Figure 1), a structure correctly predicted
by the RNA folding program used in the present study
(27,28). The pseudo-triloop is not needed for RT binding,
but is required for pgRNA encapsidation, suggesting its
interaction with capsid proteins (29,42). High conserva-
tion of T1878,G 1879 and T1880 nucleotides was observed
in our study, particularly G1879, which suggests that they
have a predominant role in the E-capsid interaction (43).
Structural and functional experiments must be performed
to analyze the effect of these changes on the HBV repli-
cation process.
The mutation combination of G1899A plus G1896A
was frequently detected in our study. Guarnieri et al.
(36) reported that G1899A does not signiﬁcantly
increase in vitro viral replication, despite signiﬁcant theor-
etical stabilization of the E structure. G1899 is found in the
Kozac sequence and precedes the start codon of HBcAg.
The reason why G1899A is a highly prevalent change, in
contrast to its paired stem position, the conserved
T1855C, remains unknown. According to our results,
the 1855T:G1899 to 1855T:A1899 change was 100 times
more frequent than the 1855T:G1899 to 1855C:G1899
change. Furthermore, in contrast to previously reported
results (36), the site-directed mutagenesis and the transfec-
tion studies showed that presence of the T1855C mutation
in both the 50- and 30-ends led to a slight, but systematic,
reduction in HBsAg, HBeAg and HBV-DNA levels. If
T1855 were to have an essential role, selection of the C
substitution would be limited and explain the low preva-
lence of this change. The most striking ﬁndings of our
study were that chimerical (but not natural) constructs
with only one 1855C mutation at the 50-o r3 0-end were
associated with higher HBsAg, HBeAg and HBV-DNA
levels than wild-type clones. Although the 50 and 30 struc-
tures have differing functions in the singular HBV repli-
cation cycle (4,5), enhancement of viral replication activity
in chimerical constructs with a single mutation remains
unexplained. Speciﬁc experiments using primary hepato-
cyte cells, such as macaque hepatocytes or other in vitro
cell systems are needed to explore the possible involve-
ment of T1855.
Analysis of nucleotide variability in the 4-nt bulge
primer (4nt primer) used as a template for synthesis of
the minus DNA strand and its corresponding AS in the
DR1 region conﬁrmed the high conservation of both
regions. It has been speculated that the 4nt primer is
more essential than DR1 AS. The existence of alternative
acceptor sites (32) is suggested, as well as the idea that 3-nt
sequences would be completely functional for minus
strand DNA synthesis (36). Our results support these
concepts because the 4nt bulge primer was slightly more
conserved than AS DR1 (99.5% versus 98.9%). As was
expected, the E structural motifs were strongly conserved
in our study; very few cases (1.47%) had different se-
quences in the 4nt primer and its canonical DR1 AS.
However, 44% showed complete 4-nt homology with the
putative acceptor site, AS3 (Positions 1849–1852), whereas
the remaining 56% showed only 3-nt homology with ca-
nonical DR1 AS or with sequences located in previously
reported alternative acceptor sites (32). Therefore, our
results seem to agree with the existence of an alternative
to the DR1 acceptor sites for the 4nt primer (32). Analysis
of the theoretical secondary structure of the 30-end E signal
(Figure 1b) showed that the AS3 sequence has tighter
Watson–Crick pairing than canonical DR1 AS. This fact
could represent an energy barrier for 4nt annealing, and
explain the low prevalence of mutated bulge variants to
enable correct annealing of 4nt with AS3.
The high cost of the pyrosequencing method used in this
research is a limit to the number of patients that can be
studied, but the large number of sequences obtained for
each patient provides deeper information on the HBV
viral quasispecies than has been previously reported. The
construct was designed to evaluate speciﬁc positions in the
preCore and polymerase regions, but not the entire gene.
Thus, our conclusions are restricted to the YMDD and
preCore regions. Because of the same cost concerns, only
LMV-treated patients were selected; other RT positions
associated with LMV and other antiviral treatments
were not included. The circular construct designed for
this study was useful for analyzing two widely separated
regions. This method can be applied to other genes if a
fragment with the two regions of interest at the ends can
be ampliﬁed by PCR.
In conclusion, UDPS study conﬁrmed the feasibility
of detecting simultaneously occurring mutations in
the preCore region and YMDD polymerase motif.
The presence of LMV-resistant variants in baseline
naı¨ve samples, detection of preCore mutations in
HBeAg-positive patients and the presence of WT
preCore variants in HBeAg-negative cases were also
demonstrated. Low percentages of defective Core
genomes and mutated HBx strains were found, illustrating
the complexity of the HBV quasispecies. Viral strains
present in small percentages can act as reservoirs and be
selected in response to external changes (e.g. administra-
tion or elimination of drug pressure, or an increased host
immune response). Genomes with mutations in the start
codon of the Core gene might result in defective particles,
whose presence might be allowed due to cooperation
between viruses. The thermodynamic stability of the E
signal was conﬁrmed to be the principal restriction for
selection of the main preCore mutation, which is respon-
sible for abolishment of HBeAg expression. Furthermore,
analysis of E signal variability revealed the essential role of
Nucleic Acids Research, 2011,Vol.39, No. 19 8469structural E motifs and possible involvement of some nu-
cleotides in E signal function. Lastly, we found that correct
annealing between the 4nt primer of the bulge and the AS
does not seem to be an absolute condition for the 4nt
primer switch needed for minus DNA strand synthesis,
suggesting that alternative cis-acting sequences, such
AS3 deﬁned in the present report, might contribute to
deﬁne the normal acceptor site in the 30 of pgRNA.
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